Novo Nordisk

What is Novo Nordisk?

Novo Nordisk, headquartered in Bagsværd, Denmark, has been a major supplier of insulin and other diabetes-care medicines for decades. In recent years it has also become prominent for its GLP-1 receptor agonist medicines, originally developed for diabetes and increasingly used for weight management.

Why investors watch Novo Nordisk

Global demand for GLP-1 medicines has drawn significant investor attention to the company, alongside its established diabetes-care business. It competes with other large pharmaceutical companies that are also developing treatments in the same therapeutic areas.

Risks and volatility

Pharmaceutical companies face patent expirations that can open the door to lower-cost competition once exclusivity ends, along with regulatory approval risk for new treatments and drug-pricing policy risk, particularly in the US market. Manufacturing capacity constraints and new competitive entrants can also affect its outlook.

Long-term investing considerations

Demand for a specific drug class can shift as new treatments and competitors emerge. When modeling long-term scenarios for a single pharmaceutical holding, test a range of assumptions rather than assuming current growth continues indefinitely.